Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | CETP | P11597 | 3/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205346 | 0.85 | CHRM2 (0.53) | VNN1MRGPRX4MAPK14CHRM2CHRM1 | |
| SCHEMBL1869446 | 0.85 | POLB (0.50) | VNN1MRGPRX4MAPK14CHRM2CHRM1 | |
| SCHEMBL27772416 | 0.85 | VNN1 (0.50) | VNN1MRGPRX4MAPK14CHRM2CHRM1 | |
| SCHEMBL11546048 | 0.84 | CHRM2 (0.51) | VNN1MRGPRX4MAPK14CHRM2CHRM1 | |
| SCHEMBL28475012 | 0.84 | VNN1 (0.56) | VNN1MRGPRX4MAPK14CHRM2CHRM1 | |
| SCHEMBL23652001 | 0.84 | VNN1 (0.51) | VNN1MRGPRX4MAPK14CHRM2CHRM1 | |
| SCHEMBL18920453 | 0.83 | SLC7A5 (0.54) | MRGPRX4SMN1; SMN2SLC7A5ROCK2ROCK1 | |
| SCHEMBL761677 | 0.83 | MAPK14 (0.54) | VNN1MRGPRX4MAPK14CHRM2CHRM1 | |
| SCHEMBL378705 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL31249652 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2MEN1KMT2ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383872-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2020-05-20 | — | — | EP | disclosed |
| EP-3383872-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2020-05-20 | — | — | EP | disclosed |
| EP-3383872-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2018-10-10 | — | — | EP | disclosed |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| CN-108349965-A | 1,3,4- thiadiazole compounds and its purposes in treating cancer | 阿斯利康(瑞典)有限公司 | 2018-07-31 | — | — | CN | disclosed |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-11-23 | — | — | US | disclosed |
| WO-2017093301-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-2004166-A2 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2008-12-24 | — | — | EP | disclosed |
| CN-101291669-A | Use of azabicyclo hexane derivatives | GLAXO GROUP LTD (GB) | 2008-10-22 | — | — | CN | disclosed |
| EP-1917013-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2007-12-20 | — | — | US | disclosed |
| WO-2007120528-A2 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| WO-2007022980-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| EP-1745040-A1 | AZABICYCLO(3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005080382-A1 | AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | DRD3, DRD1, DRD2 | VNN1 2635/4885MRGPRX4 675/4885SMN1; SMN2 4810/4885 |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | GLS2, GLS, GLRX3 | VNN1 2633/4885MRGPRX4 2080/4885SMN1; SMN2 4479/4885 |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLRX3 | VNN1 2633/4885MRGPRX4 2080/4885SMN1; SMN2 4479/4885 |
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | VCAM1, AOC3, AOC2 | VNN1 146/4885MRGPRX4 2218/4885SMN1; SMN2 305/4885 |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | ADH1C, PKD1, HTT | VNN1 4465/4885MRGPRX4 3365/4885SMN1; SMN2 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.